What Happens to Patients on Antiretroviral Therapy Who Transfer Out to Another Facility? by Kwong-Leung Yu, Joseph et al.
What Happens to Patients on Antiretroviral Therapy Who
Transfer Out to Another Facility?
Joseph Kwong-Leung Yu
1,2,3,4, Teck-Siang Tok
2, Jih-Jin Tsai
3, Wu-Shou Chang
4, Rose K. Dzimadzi
5, Ping-
Hsiang Yen
2, Simon D. Makombe
6, Amon Nkhata
6, Erik J. Schouten
6,7, Kelita Kamoto
6, Anthony D.
Harries
6,8,9*
1Taiwan Medical Mission in Malawi, Mzuzu Central Hospital, Mzuzu, Malawi, 2International Medical Cooperation and Development Center, Pingtung Christian Hospital,
Pingtung, Taiwan, 3College of Medicine, Kaohsiung Medical University Division of Infectious Disease, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 4Bureau
of International Cooperation, Department of Health, Taipei, Taiwan, 5Office of the Hospital Director, Mzuzu Central Hospital, Ministry of Health, Mzuzu, Malawi, 6HIV Unit,
Ministry of Health, Lilongwe, Malawi, 7Management Sciences for Health, Lilongwe, Malawi, 8Family Health International, Lilongwe, Malawi, 9London School of Hygiene
and Tropical Medicine, London, United Kingdom
Abstract
Background: Long term retention of patients on antiretroviral therapy (ART) in Africa’s rapidly expanding programmes is
said to be 60% at 2 years. Many reports from African ART programmes make little mention of patients who are transferred
out to another facility, yet Malawi’s national figures show a transfer out of 9%. There is no published information about what
happens to patients who transfer-out, but this is important because if they transfer-in and stay alive in these other facilities
then national retention figures will be better than previously reported.
Methodology/Principal Findings: Of all patients started on ART over a three year period in Mzuzu Central Hospital, North
Region, Malawi, those who transferred out were identified from the ART register and master cards. Clinic staff attempted to
trace these patients to determine whether they had transferred in to a new ART facility and their outcome status. There
were 805 patients (19% of the total cohort) who transferred out, of whom 737 (92%) were traced as having transferred in to
a new ART facility, with a median time of 1.3 months between transferring-out and transferring-in. Survival probability was
superior and deaths were lower in the transfer-out patients compared with those who did not transfer.
Conclusion/Significance: In Mzuzu Central Hospital, patients who transfer-out constitute a large proportion of patients not
retained on ART at their original clinic of registration. Good documentation of transfer-outs and transfer-ins are needed to
keep track of national outcomes. Furthermore, the current practice of regarding transfer-outs as being double counted in
national cohorts and subtracting this number from the total national registrations to get the number of new patients
started on ART is correct.
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Introduction
Malawi, a small resource-poor country in Southern Africa, has
been making good progress with scaling up antiretroviral therapy
(ART): by June 2007, just over 110,000 patients had started free
treatment from 109 public sector facilities [1]. Treatment outcomes
are monitored every quarter, with patients classified as alive and on
treatment, dead, stopped treatment, transferred to another facility or
‘‘lost to follow-up’’. The category of transfer-out is used in both the
ART programme and national TB programme to indicate patients
who activelyseeka transferto anothertreatment facility.Asnewsites
are continuously being accredited for ART delivery, many patients
who are started on therapy in a distant hospital obviously prefer to
continue with therapy from a facility nearer to home and therefore
transfer. By June 2006, there were 9,862 patients (9% of the total
cohort) who had been recorded as transfer-out in the ART registers
from around the country [1].
There is recent concern about the poor retention on therapy in
ART programmes in sub-Saharan Africa [2,3]. Reports on
treatment outcomes from individual ART clinics in sub-Saharan
Africa often raise the problem of loss to follow-up [4–9]. However,
surprisingly little mention is made of transfer-outs, with one study
from Botswana mentioning a transfer-out rate of 5.2% [4], and
one from South Africa mentioning this as a small component of
loss to follow-up [5]. We know from the Malawi national quarterly
ART reports that transfer-outs are a common cause of patients no
longer being retained on therapy in their original ART clinic.
However, we have no hard data on whether these patients
transfer-in to another facility and we do not know how they fare in
terms of treatment outcomes once registered in the new facility.
We therefore conducted a study in the Northern Region of Malawi
to investigate this issue, and to determine what had happened to
patients who transferred out from Mzuzu Central Hospital to
other facilities.
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Background
Details of how ART in Malawi is delivered and monitored have
previously been described [10]. When patients start ART, their
details are entered into ART patient master cards and an ART
register, and patients are given a unique ART identification
number. Every month patients come for clinic reviews, at which
time their outcome status is entered into the master card and they
are given another supply of ART drugs for a month. If a patient
wishes to transfer to another facility, the name of the new facility to
which the patient will move is indicated in the ART register and
the treatment outcome is changed to transfer-out. The patient is
given his/her ART master card, a transfer out letter and a month’s
supply of drugs to take to the new facility. A copy of the original
master card is made and kept in the usual numerical order in the
arch-back files in the original clinic [10]. Thus, ART staff and staff
from supervising teams can see who has transferred out from each
clinic by going through the ART patient master cards and the
register.
At the new facility, the patient is registered with a new ART
identification number related to that facility. The patient hands
over his/her master card from the previous site, and on this master
card the ART identification number is changed to the new
number. This master card is then filed in the usual way and used
until the end of the year, at which time a new master card is issued
to the patient. In both the ART register and the ART master card
it is clearly written that the patient is a ‘‘transfer-in’’.
Data collection and Analysis
The master cards and the ART register of all new patients
registered at Mzuzu Central Hospital, Northern Region, Malawi,
between June 2004 and December 2006 were reviewed, and a
record was made of those who had transferred out to another
facility. For patients who had transferred out within the Northern
Region, active visits were made to all the ART clinics in that
region to determine whether patients had in fact transferred-in, the
date of the transfer-in and their latest treatment outcome with the
date. Treatment outcomes of patients transferring in were
censored on March 31
st 2007. Patients alive and on ART on
March 31
st, 2007, were recorded as such. However, those who had
died, were lost to follow-up, stopped therapy or transferred-out
again before this date were recorded as such with the date of this
outcome. For patients transferring to the Central or Southern
Region, active follow-up was confined to making a phone call to
the new site to try and obtain data similar to that obtained during
Northern Region site visits.
Categorical variables between patients who transferred out and
who did not transfer out were analyzed and compared using the
chi-squared test with odds ratios (OR) and the chi-squared test for
trend. The probability of survival between patients who trans-
ferred out and were traced and patients who did not transfer-out
was estimated using the Kaplan-Meier method, and comparisons
made using the Cox-Mantel (Log rank test). The level of
significance was set at P=0.05 or less, and 95% confidence
intervals (CI) were used throughout. Data analysis was carried out
using SAS system for Windows (Version 8.01).
Ethical Approval
The Malawi National Health Science Research Committee
provides general oversight and approval for the collection and use
of routine programmatic data for monitoring and evaluation, as
was the case with this study.
Results
There were 4175 patients registered for ART, of whom 805
(19%) had transferred out to another facility, 65 patients
transferring to the Central and Southern Regions and 740 to
the Northern Region. Altogether, 737 (92%) of these patients were
traced. Tracing was successful in 16 (25%) of 65 patients who
transferred to the Central and South region and 721 (98%) 740
patients who transferred to the Northern Region.
Characteristics and treatment outcome status of patients who
transferred out and were traced compared with those who did not
transfer out are shown in Table 1. There was a trend for those
transferring out to have less advanced clinical stage of disease
(WHO Clinical Stage 1,2 or 3 together) compared with those who
did not transfer out. The proportion of transfer-out patients who
died was significantly less than those who did not transfer out [OR
Table 1. Characteristics and treatment outcomes of patients
who transferred out and those who did not transfer out from
Mzuzu Central Hospital, Malawi, between June 2004 and
December 2006.
Patients
transferring
out
Patients not
transferring
out P value
Number of patients started on
ART
805 3370
Female patients 491 (61%) 1977 (59%) NS
Children (aged,15 years) 81 (10%) 396 (12%) NS
Median age in years 36 37 NS
Indication for ART:
WHO Stage 1 or 2 with low CD4
count
56 (7%) 530 (16%) p=0.016
b
WHO Clinical Stage 3 620 (77%) 2186 (65%)
WHO Clinical Stage 4 129 (16%) 654 (19%)
Patients transferring out and not
traced
68
Patients transferring out and
traced
737
Median time (range) in months
between transfer out and transfer
in those traced
1.3 (0.03–3.53)
Treatment outcome status
a
Alive and on ART 634 (86%) 2826 (84%) NS
Dead 40 (5%) 423 (12.5%) p,0.001
Lost to follow-up 22 (4%) 120 (3.5%) NS
Stopped treatment 0 1 NS
Transferred out again 41 (5%) Not applicable
Month of death after start of ART in the original or the new facility for those
who had transferred out:
Month 1 0 180 (42.5%)
Month 2 4 (10%) 74 (17.5%) p=,0.001
c
Month 3 5 (12.5%) 43 (10%)
After month 3 31 (77.5%) 126 (30%)
atreatment outcomes censored on March 31
st, 2007, and for those who
transferred out these refer to those who were traced.
bchi-squared test for trend=5.8.
cchi-squared test for trend=42.3.
WHO=World Health Organization; ART=antiretroviral therapy.
doi:10.1371/journal.pone.0002065.t001
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die, there was a significant trend towards later deaths compared
with those who did not transfer out. There was a significantly
higher survival probability in patients transferring out and traced
compared with those who did not (Figure 1).
Discussion
This study shows first of all that almost one fifth of patients
transferred out from a central hospital institution over a 30-month
period as new ART sites were set up in the country and started to
deliver therapy closer to patients’ homes. For geographical reasons
more patients transferred out to new sites in the Northern Region
compared to the other 2 regions in the country.
Second, we were able to document that over 90% of these
patients transferred in to a new facility. Tracing was more
successful in the Northern Region where active follow-up was
conducted to sites compared with the other 2 regions of the
country where only telephone calls could be made. The median
time for the transfer process was just over 1 month, which suggests
that patients who usually move with a new 1-month’s supply of
drugs probably do not experience drug interruptions during the
transfer process, an important factor in reducing the development
of drug resistance. The reasons for not finding what happened to
some transfer out patients are speculative. These patients may
have transferred to a different site altogether either within or
outside of Malawi, they may have used a different name to transfer
to another site, or they may have died or decided to stop therapy.
Third, the probability of survival in patients transferring out was
better than those who remained at the central hospital, suggesting
that transfers occur after patients have stabilised on therapy and
after the first three months when a large proportion of ART deaths
occur [5,9].
There are two important lessons from this study. First, two
recent published reports have emphasised that there is poor
retention on therapy in Africa’s ART programmes, citing loss to
follow-up and death as the principal reasons for attrition [2,3]. We
feel that these reports are potentially misleading, and that one of
the important reasons for poor ART clinic retention is the transfer
out of patients who move to another site yet continue to
successfully take ART. In Malawi’s well organised tuberculosis
programme, there were poor quality data on transfers [11], and in
Malawi’s national ART programme we are well aware that
patients may transfer-out without informing the original clinic, and
these patients will be counted as ‘‘losses to follow-up’’ unless active
tracing is conducted [12]. Second, in Malawi we have thought for
some time that patients who transfer out may be double counted,
in their original ART site as a transfer-out and in the new site with
a new number as alive and on therapy. To allow for this at
national level, when we count the number of new patients starting
on therapy we subtract the transfer-outs from the total national
registrations. The current study validates this approach, as over
90% of patients who transfer-out are indeed registered at a new
site and the majority of those registered are subsequently found
alive and on ART.
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Figure 1. Probability of Survival in Patients on ART who
Transfer Out and who do not Transfer Out.
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